CV Sciences (CVSI) Acquisitions (2013 - 2024)
CV Sciences' (CVSI) quarterly Acquisitions came in at $4000.0 in Q4 2024, down 97.44% year-on-year from $156000.0 in Q1 2024, and up 111.76% quarter-over-quarter from -$34000.0 in Q3 2024.
CV Sciences (CVSI) Acquisitions (2013 - 2024) Analysis & Trends
CV Sciences has disclosed Acquisitions across 3 years of filings, most recently posting $4000.0 for Q4 2024.
- Acquisitions for Q4 2024 came in at $4000.0, down 97.44% year-over-year; the trailing twelve-month figure through Dec 2025 was -$30000.0 (down 123.81% YoY), and the FY2024 annual result was $10000.0, down 93.59% from the prior year.
- Acquisitions came in at $4000.0 for Q4 2024 at CV Sciences, up from -$34000.0 in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $156000.0 in Q4 2023 to a low of -$34000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.09 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 137.87 Mn |
| 10 | CV Sciences | - | - | 1.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | -34,000.00 |
| Dec 31, 2023 | 156,000.00 |
| Mar 31, 2013 | 50,775.00 |